Novartis

Category

Novartis Pays $50m Upfront Cash for License and Stock in Mesoblast to Access Mesenchymal Stromal Cells Regenerative Therapy Platform

Novartis recently inked an exclusive worldwide license and collaboration agreement with regenerative therapy venture Mesoblast to develop, commercialize and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that...

Cincinnati Children’s Investigator Idea May Lead to Answer to COVID-19 Deadly Cytokine Storm: Ruxolitinib

Cincinnati Children’s researchers initially developed a transgenic mouse to model HLH (hemophagocytic lymphohistiocytosis), a deadly childhood immune disease but as it now turns out this effort may end up saving lives during the COVID-19 pandemic. Cincinnati...

Baby Pia Denied Compassionate Use: Something ‘Ain’t’ Right in Basel

Novartis just can’t keep out of bad news. They have denied a request from the Belgian federal government to make the most expensive drug in the world (Zolgensma at $2 million) available to a Belgian toddler named Pia who suffers from spinal muscular atrophy, despite...

Pin It on Pinterest